BEHOLD-Ovarian01 is designed to determine whether mocertatug rezetecan can improve clinically meaningful outcomes in a population facing limited therapeutic options. The trial follows encouraging activity reported from the Phase 1 BEHOLD-1 study, where responses were observed across patient subgroups relevant to real-world platinum-resistant disease.

Mocertatug rezetecan (Mo-Rez; GSK5733584) targets B7-H4, an immune checkpoint receptor expressed in approximately 70–90% of ovarian cancers but with minimal expression in most normal adult tissues. This differential expression is intended to create a favorable therapeutic window for selective ADC delivery.

Mechanistically, Mo-Rez pairs a B7-H4–directed monoclonal antibody with a topoisomerase I inhibitor payload. After binding to B7-H4–expressing tumor cells, the ADC is internalized, delivering the cytotoxic payload to disrupt DNA replication and drive tumor cell death.

In BEHOLD-1, the Phase 3 dose selection was 5.8 mg/kg. At that dose, the confirmed objective response rate was 62%, with responses spanning a range of B7-H4 expression levels. Notably, activity was also reported in clinically relevant groups, including patients previously treated with bevacizumab and PARP inhibitors.

The trial population in BEHOLD-Ovarian01 reflects a previously treated setting, where platinum-resistant ovarian cancer remains difficult to manage. Standard approaches often rely on non-platinum chemotherapy such as weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan, with or without bevacizumab.

The Phase 3 design is randomized, open-label, and multicenter, comparing Mo-Rez with investigator’s choice chemotherapy. Study stakeholders include global cooperative groups such as ENGOT, APGOT, and LACOG, with The GOG Foundation contributing trial leadership and operational expertise.

Collectively, BEHOLD-Ovarian01 aims to establish whether B7-H4–targeted ADC therapy can translate early pharmacology and antitumor signals into improved progression-free and overall survival for patients with platinum-resistant ovarian cancer.

Subject of Research: People; clinical trial in platinum-resistant ovarian cancer
Article Title: GOG-3132/BEHOLD-Ovarian01 Enrolls First Patient to Test Mocertatug Rezetecan in Platinum-resistant Ovarian Cancer
News Publication Date: July 27, 2026
Web References: http://www.gog.org ; https://engot.esgo.org/ ; NCT07286266
References: Included in the source content (Oaknin A et al., Porter JM et al., and multiple ovarian cancer treatment references)
Image Credits: The GOG Foundation, Inc.

Keywords: mocertatug rezetecan; GSK5733584; B7-H4; antibody-drug conjugate; ovarian cancer; platinum-resistant; Phase 3; BEHOLD-Ovarian01; NCT07286266; ENGOT

Platinum-resistant ovarian cancer presents a critical unmet need in oncology, characterized by rapid disease progression following platinum-based chemotherapy—a cornerstone of ovarian cancer treatment. As tumor cells adopt mechanisms to evade immune clearance, including the upregulation of “don’t eat me” signals like CD47, therapeutic options become severely limited. This biological insight underpins the strategic rationale behind therapeutics like SL-172154, which simultaneously blocks CD47 to promote phagocytosis of tumor cells by macrophages, while activating CD40 to enhance antigen presentation and stimulate T-cell responses. By harnessing the dual actions of this bispecific protein, scientists hope to turn the tide against cancers that have developed sophisticated immune evasion strategies.

The trial setup involved combining SL-172154 with two established agents: mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor alpha frequently overexpressed on ovarian cancer cells, and pegylated liposomal doxorubicin (PLD), a chemotherapeutic with a favorable toxicity profile used in recurrent disease. This pairing aims to leverage SL-172154’s immune-modulating properties alongside the direct cytotoxic effects of these drugs, hopeful that such integration will foster heightened tumor cell phagocytosis and invigorate adaptive immune responses. The design reflects a nuanced approach to counter the complex, immunosuppressive tumor microenvironment emblematic of PROC.

The clinical trial results reported in the British Journal of Cancer reveal encouraging signals about the safety profile and preliminary efficacy of these combinations. Patients treated with SL-172154 in conjunction with either MIRV or PLD experienced manageable adverse effects, demonstrating acceptable tolerability for this novel regimen. Importantly, biomarker analyses indicated increased macrophage infiltration and evidence of enhanced antigen presentation, corroborating the hypothesized mechanistic actions of SL-172154. Such immune activation could signify a pivotal breakthrough in the immunotherapeutic landscape for this particularly recalcitrant subtype of ovarian cancer.

Beyond safety and mechanistic validation, the trial unveiled preliminary signs of clinical benefit, with several participants exhibiting disease stabilization or modest tumor shrinkage—uncommon in the context of platinum resistance. Though early-stage, such findings ignite cautious optimism that engaging innate and adaptive immunity together might overcome therapeutic resistance and extend patient survival in a condition notoriously marked by poor outcomes. This trial thus sets the stage for larger, more definitive studies, opening avenues for future exploration into combination immunotherapy regimens.

At a molecular level, the dual targeting strategy of SL-172154 exemplifies a sophisticated approach designed to circumvent tumor immune escape. CD47, often termed a “don’t eat me” signal, allows cancer cells to evade phagocytosis by binding to signal regulatory protein alpha (SIRPα) on macrophages. By blocking CD47, SL-172154 disarms this defense, enabling macrophages to engulf and eliminate malignant cells. Concurrently, CD40 activation on dendritic cells and macrophages promotes maturation and enhanced antigen presentation to cytotoxic T lymphocytes, inspiring a robust adaptive immune response. This synergy is pivotal in transforming the tumor microenvironment from immunosuppressive to immunostimulatory.

The choice to test SL-172154 in combination with mirvetuximab soravtansine is particularly strategic. MIRV specifically targets folate receptor alpha—a distinct molecular signature of many ovarian cancers—delivering potent cytotoxic payloads directly to tumor cells. This selective attack may induce immunogenic cell death, releasing tumor antigens that are then more effectively presented to T cells via CD40 activation, facilitating a dialog between innate and adaptive immunity. Such rational combinations exemplify precision immuno-oncology, where molecular targeting and immune modulation converge.

Additionally, the combination with pegylated liposomal doxorubicin leverages the chemotherapeutic’s ability to induce tumor cell stress and death while limiting toxic side effects, maintaining patients’ quality of life during treatment. Its integration with SL-172154 aims to prime the immune system through immunogenic cell death pathways while fostering macrophage-mediated clearance via CD47 blockade. This multifaceted attack highlights the sophisticated interplay being harnessed to circumvent tumor resilience and improve patient outcomes.

An intriguing facet emerging from this research is the potential for SL-172154 to act as a backbone immunomodulatory agent, capable of augmenting the efficacy of diverse anti-cancer therapies beyond ovarian cancer. By recalibrating the immune tumor microenvironment and enhancing antigen-specific T cell responses, SL-172154 introduces a versatile tool against malignancies characterized by immune evasion and chemotherapy resistance. Its bispecific design represents a new paradigm in immunotherapy, breaking traditional mono-target approaches and engendering synergistic immunologic effects.

Despite the promising results, challenges remain before SL-172154 can be integrated into routine clinical practice. Larger randomized trials are necessary to confirm efficacy signals, refine dosing, and delineate patient populations most likely to benefit. Mechanisms of resistance to CD47/CD40 targeting, downstream immune regulation, and long-term effects require further elucidation. Nonetheless, the current findings lay a robust foundation for subsequent investigation and underscore the critical importance of innovative immunotherapeutic strategies in transforming the treatment landscape for PROC.

Parallel to clinical development, translational studies probing the molecular and cellular underpinnings of responses to SL-172154 are underway. These investigations aim to identify predictive biomarkers of response and resistance, map immune cell dynamics, and characterize alterations in the tumor microenvironment induced by therapy. Such insights will inform biomarker-driven patient selection and rational combination regimens, fostering a precision medicine framework tailored to overcome the heterogeneity and complexity of ovarian cancer.

Moreover, the trial underscores the value of exploiting immune checkpoints beyond the canonical PD-1/PD-L1 axis. Targeting CD47 and harnessing CD40 agonism carve alternative routes to immune reactivation, expanding the armamentarium of immunotherapeutic approaches. This diversification is crucial to outpace adaptive tumor escape mechanisms and achieve durable, meaningful clinical responses in cancers traditionally refractory to immunotherapy.

The implications of this study reverberate beyond ovarian cancer, illuminating pathways applicable to other solid tumors where CD47 overexpression and immune suppression hinder therapeutic success. The dual mechanism of SL-172154 offers a blueprint for designing next-generation bispecific fusion proteins capable of orchestrating multifaceted immune responses tailored to distinct tumor ecosystems. As immuno-oncology advances, such biologics embody the cutting edge of therapeutic innovation.

In conclusion, the Phase Ib trial of SL-172154 combined with mirvetuximab or pegylated liposomal doxorubicin marks a significant milestone in the quest to conquer platinum-resistant ovarian cancer. By unleashing macrophage-mediated phagocytosis and invigorating T cell immunity through a bispecific approach, this novel agent heralds a new frontier in immunotherapy. While challenges remain, the promise of durable clinical benefit fuels hope for patients facing a daunting diagnosis. This innovative strategy underscores the transformative potential of harnessing innate and adaptive immunity synergistically—a beacon lighting the way toward improved survival and quality of life in ovarian cancer.

As the oncology community eagerly anticipates expanded trials and real-world applications, the fusion of molecular insight and immunologic engineering embodied by SL-172154 exemplifies the future of cancer therapy. The pursuit of comprehensive immune engagement heralds an era where therapeutic resistance might be overcome through tailored, dynamic interventions. Beyond scientific advancement, this progress resonates profoundly with patients and families, embodying hope and renewed prospects in the battle against ovarian cancer’s most intractable forms.

Subject of Research: Novel immunotherapeutic strategies targeting CD47 and CD40 pathways in platinum-resistant ovarian cancer.

Article Title: Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Article References:
Drew, Y., Gilbert, L., Martinez Bueno, A. et al. Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03430-0

Image Credits: AI Generated

DOI: 08 April 2026